DARZALEX net trade sales rose to $14.35 billion in 2025 from $11.67 billion in 2024, driven by U.S. sales of $8.27 billion (up from $6.59 billion) and international sales of $6.08 billion (up from $5.08 billion), reflecting broader adoption and uptake of the subcutaneous DARZALEX FASPRO formulation. The drug remains a key revenue driver for Genmab via its global royalty agreement with Johnson & Johnson; Genmab will report full-year 2025 results on February 17, 2026. Shares have traded between $17.24 and $35.43 over the past year and were trading pre-market at $32.00, up 2.14%.
Market structure: DARZALEX’s $14.35bn 2025 sales (up ~23% YoY from $11.67bn) disproportionately benefits Genmab (GMAB via royalties) and Johnson & Johnson (JNJ via Janssen sales), strengthens DARZALEX’s CD38 franchise and increases Janssen’s pricing/volume leverage in myeloma. Competitors in the myeloma class face share loss and pricing pressure as subcutaneous uptake lowers administration friction; payers become marginal losers because utilization (and short-term spend) increases. Supply/demand: demand is accelerating (US $8.27bn vs international $6.08bn) and subcutaneous formulation raises throughput, implying sustained volume growth but increasing sensitivity to manufacturing/COGS shocks. Cross-asset: expect GMAB equity volatility to stay elevated into Feb 17, 2026 results, modest tightening of JNJ credit spreads, and limited FX or commodity exposure. Risk assessment: tail risks include biosimilar competition or adverse label/regulatory actions within 3–5 years that could cut peak DARZALEX revenue by 30–50%, royalty disputes or manufacturing disruptions at Janssen creating 20–40% near-term hits, and payer-driven price concessions within 12–24 months. Immediate (days) risk is headline/earnings reaction; short-term (weeks–months) is execution and supply cadence; long-term (years) is IP expiry/competition. Hidden dependencies: Genmab’s cash flow is a function of JNJ’s net pricing/volume and third-party rebates; adverse changes to US Medicare policy or European tendering would have outsized second-order effects. Key catalysts: Genmab’s Feb 17, 2026 annual results, upcoming JNJ quarterly reports, and any FDA/EMA biosimilar approvals in the next 6–24 months. Trade implications: direct play is long GMAB equity for leverage to DARZALEX growth; size 2–3% NAV ahead of Feb 17, 2026 to capture momentum and potential re-rating, with a 15% stop. If options liquidity allows, buy a Mar 2026 GMAB 35/45 call spread sized to 0.5–1.0% NAV to cap premium and target ~>30% upside; hedge tail with 3-month 15% OTM puts covering 30% of position. Add a 1–2% tactical overweight in JNJ as defensive, income-generating exposure (sell 1–2 month 2–3% OTM covered calls) to monetize near-term stability while limiting downside. Contrarian angles: the market may underappreciate how much subcutaneous DARZALEX increases lifetime patient penetration — imply 5–7% incremental TAM expansion over 3 years — which would favor GMAB’s multiple expansion more than current consensus. Conversely, consensus may be complacent about long-term biosimilar risk: historical parallels (e.g., Rituxan) show rapid revenue erosion post-competitor entry, so a prudent valuation implies scenario-weighted downside of 30–50% in a 3–5 year adverse outcome. Unintended consequence: heavy marketing to drive uptake could accelerate payers’ push for price caps, creating a convex risk to near-term margins.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.60
Ticker Sentiment
